Mammary Cell News Volume 3.05 | Feb 10 2011

 Cell Therapy News is now on Facebook. Join us!

 Follow us on Twitter! @MammaryCell

Interested in recruiting talented individuals? Post your career opportunities in Mammary Cell News at no cost. Contact us at info@connexoncreative.com

Destined for Disease: Breast Cancer Mutation Regulates Cell Fate
A new study sheds light on why individuals who inherit a particular family of mutations have a high risk of developing a very aggressive form of breast cancer. [Press release from ScienceDaily discussing online prepublication in Cell Stem Cell]

Limited Lymph Node Removal for Certain Breast Cancer Does Not Appear to Result in Poorer Survival
Among patients with early-stage breast cancer that had spread to a nearby lymph node and who received treatment that included lumpectomy and radiation therapy, women who just had the sentinel lymph node removed did not have worse survival than women who had more extensive axillary lymph node dissection, according to a study. [Press release from ScienceDaily discussing online prepublication in The Journal of the American Medical Association]

ETV6-NTRK3–Mediated Breast Epithelial Cell Transformation Is Blocked by Targeting the IGF1R Signaling Pathway
Investigators describe a breast cancer model based on expression of the ETV6-NTRK3 chimeric tyrosine kinase that suggests novel therapeutic applications of insulin-like growth factor 1 receptor (IGF1R) inhibitors in secretory breast cancers. [Cancer Res]

Heat Shock Protein Hsp72 Plays an Essential Role in Her2-Induced Mammary Tumorigenesis
Scientists investigated the role of Hsp72 in Her2 oncogene-induced neoplastic transformation and tumorigenesis. [Oncogene]

Vaccination With Human Anti-Trastuzumab Anti-Idiotype scFv Reverses HER2 Immunological Tolerance and Induces Tumor Immunity in MMTV.f.huHER2(Fo5) Mice
Investigators tested whether trastuzumab-selected single-chain Fv (scFv) could be used to develop an anti-idiotype-based vaccine to inhibit growth of HER2-positive tumor cells in vitro and in vivo through induction of long-lasting HER-specific immunity. [Breast Cancer Res]

Adipose Progenitor Cells Increase Fibronectin Matrix Strain and Unfolding in Breast Tumors
Researchers utilized a combination of biochemical and physical science tools to evaluate whether paracrine signaling between breast cancer cells and adipose progenitor cells regulates fibronectin matrix assembly and stiffness enhancement in the tumor stroma. [Phys Biol]

CLINICAL RESEARCH

Axillary Dissection vs No Axillary Dissection in Women With Invasive Breast Cancer and Sentinel Node Metastasis
The objective of this study is to determine the effects of complete axillary lymph node dissection on survival of patients with sentinel lymph node metastasis of breast cancer. [JAMA]

Genetic Predisposition Directs Breast Cancer Phenotype by Dictating Progenitor Cell Fate
Investigators report here that breast epithelial cells derived from patients harboring deleterious mutations in BRCA1 (BRCA1^mut/+) give rise to tumors with increased basal differentiation relative to cells from BRCA1^+/+ patients. [Cell Stem Cell]

Outcomes of Positron Emission Tomography-Staged Clinical N3 Breast Cancer Treated with Neoadjuvant Chemotherapy, Surgery, and Radiotherapy
The purpose of this study is to evaluate the treatment outcome and efficacy of regional lymph node irradiation after neoadjuvant chemotherapy and surgery in positron emission tomography-positive clinical N3 breast cancer patients. [Int J Radiat Oncol Biol Phys]

UCLB & BD Reach Exclusive License Agreement
UCL Business (UCLB) and BD (Becton, Dickinson and Company) announced an agreement aimed at improving the early detection of ovarian and breast cancers to ultimately enable earlier and more effective treatment. [University College London (UCL) Business Press Release]

Pfizer Said to Pay $330 Million in Prempro Settlement
Pfizer Inc. agreed to pay about $330 million to resolve claims that its Prempro menopause drug caused breast cancer, in the first large-scale settlements in eight years of litigation, two people familiar with the accords said. [Bloomberg BusinessWeek]

Lab Technologist – Human Embryonic and Induced Pluripotent Stem Cells (STEMCELL Technologies)
 
Lab Technologist – Tissue Culture (STEMCELL Technologies)

Assistant Professor (University of Pittsburgh School of Medicine, Center for Cellular and Molecular Engineering)

Post-doctoral Position (University of Pittsburgh)

Post-doctoral Position in Biochemistry/Molecular Cancer Research (Université d’Auvergne)

Post-doctoral Position (National Cancer Centre Singapore)

Post-doctoral Position (Wayne State University School of Medicine)

Post-doctoral Research Associate (University of Wisconsin-Madison)

Post-doctoral Position – Germline Stem Cells (R. L. Brinster, School of Veterinary Medicine, University of Pennsylvania)

Field Applications Specialist – Cell Therapy (Medical) (Pall Corporation)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities with the Connexon Creative Job Board at no cost.

Visit here to post your career opportunities.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.